Canadian healthcare ads must not be false or misleading about providers, credentials or affiliations, and performance claims must be based on adequate and proper testing.
Competition Act ss. 52, 74.01(1)(a)-(b), 74.03(5)
What is Canada Competition Act - False/Misleading Healthcare Advertising?
Canadian healthcare ads must not be false or misleading about providers, credentials or affiliations, and performance claims must be based on adequate and proper testing. Canadian healthcare marketing referencing provider credentials, affiliations, specialties or treatment outcomes. This guide summarizes the supplied rule information for marketing review. Use the linked official source to confirm the current text, applicability and any exceptions
general_audience, general_adults_18plus, customers · Healthcare Services, Specialty Clinics, Hospitals Health Systems · healthcare
Where does this rule apply?
Canada
Which marketing channels are covered?
all_channels
When does this rule take effect?
2026-05-10
What does this rule require?
Canadian healthcare ads must not be false or misleading about providers, credentials or affiliations, and performance claims must be based on adequate and proper testing.
How can marketing teams comply?
Canadian healthcare marketing referencing provider credentials, affiliations, specialties or treatment outcomes.
What is Canada Competition Act - False/Misleading Healthcare Advertising?
Canadian healthcare ads must not be false or misleading about providers, credentials or affiliations, and performance claims must be based on adequate and proper testing.
Who does this rule apply to?
general_audience, general_adults_18plus, customers · Healthcare Services, Specialty Clinics, Hospitals Health Systems · healthcare
Canadian environmental claims must not mislead: product claims need adequate and proper testing and business claims need adequate and proper substantiation, under Competition Act s.74.01(1)(b.1)-(b.2) as amended by C-59 and C-15.
EU financial and crypto firms must not claim AMLA supervision or endorsement they do not have, or present AML compliance as an absolute guarantee, since this misleads consumers under the UCPD.
Australian businesses must not make false or misleading claims about a service's standard or quality, about performance, benefits, sponsorship or approval, or about the nature or suitability of goods and services.
Australian businesses must not make false or misleading claims that goods are of a particular quality, grade, composition, style, model or history, that they are new, about their price, or about their place of origin.
Corporations Act s 1041H and ASIC Act s 12DA prohibit misleading product labels and feature claims, including absolute or unexplained sustainability claims, which ASIC enforced in its 2024-2025 greenwashing penalty cases.
From Nov 12, 2026, federal law excludes synthesized cannabinoids (such as delta-8 made from CBD) and final hemp products over 0.4 mg total THC per container from the definition of hemp, and many states ban intoxicating hemp products; ads may not offer them as lawful hemp.
Request a free compliance scan of your homepage and book a time with Warrant.